Compare CRS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRS | RPRX |
|---|---|---|
| Founded | 1910 | 1996 |
| Country | United States | United States |
| Employees | 4500 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3B | 19.5B |
| IPO Year | 1994 | 2020 |
| Metric | CRS | RPRX |
|---|---|---|
| Price | $434.75 | $48.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $401.50 | $47.75 |
| AVG Volume (30 Days) | 741.8K | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 0.19% | ★ 1.95% |
| EPS Growth | ★ 100.54 | N/A |
| EPS | ★ 4.52 | 1.78 |
| Revenue | $2,157,700,000.00 | ★ $2,378,193,000.00 |
| Revenue This Year | $9.17 | $38.30 |
| Revenue Next Year | $10.54 | $4.80 |
| P/E Ratio | $95.57 | ★ $27.14 |
| Revenue Growth | ★ 20.03 | 5.06 |
| 52 Week Low | $165.00 | $31.58 |
| 52 Week High | $442.88 | $49.06 |
| Indicator | CRS | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 64.06 | 63.70 |
| Support Level | $297.11 | $35.32 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 19.09 | 1.00 |
| MACD | 3.92 | 0.08 |
| Stochastic Oscillator | 89.49 | 88.11 |
Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.